VIDEO: Aerie updates Rhopressa, Rocklatan programs

ByTom Mitro

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN FRANCISCO — At Glaucoma 360: New Horizons Forum, Thomas A. Mitro, president and chief operating officer of Aerie Pharmaceuticals, updates the company’s progress with Rhopressa (netarsudil ophthalmic solution 0.02%) and Rocklatan (netarsudil 0.02% and latanoprost 0.005% ophthalmic solution), and discusses receiving the Glaucoma Research Foundation’s Catalyst Award.